Samjin Pharmaceutical announced on July 6 that it has officially launched 'Pulversed Injection (fulvestrant)', a breast cancer treatment indicated for use as both monotherapy and combination therapy in patients with advanced or metastatic breast cancer.

Breast Cancer Treatment 'Pulversed Injection'. Samjin Pharmaceutical

Breast Cancer Treatment 'Pulversed Injection'. Samjin Pharmaceutical

View original image

'Pulversed Injection' is a selective estrogen receptor degrader (SERD) that targets and degrades estrogen receptors. With this mechanism of action, it offers sustained therapeutic effects even for patients who have developed resistance to existing hormone therapies.


The target patient group for 'Pulversed Injection' includes those with 'HR+ (hormone receptor-positive)' and 'HER2- (human epidermal growth factor receptor 2-negative)' breast cancer, which together account for about 70% of breast cancer cases in Korea. Specifically, it is approved for a broad range of indications in women with advanced or metastatic breast cancer, both pre- and post-menopause: as a first-line monotherapy, and in combination as a first- or second-line therapy with major CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) for patients whose disease has progressed following endocrine therapy. This wide range of indications is expected to enable diverse therapeutic approaches in clinical practice.


The main ingredient of 'Pulversed Injection', fulvestrant, has already demonstrated excellent efficacy in large-scale global clinical trials. In the FALCON phase 3 clinical trial, fulvestrant significantly extended progression-free survival (PFS) compared to the control drug anastrozole in postmenopausal breast cancer patients who had not received prior endocrine therapy. Furthermore, in the CONFIRM clinical trial targeting patients whose disease had progressed after first-line endocrine therapy, fulvestrant was shown to reduce the risk of disease progression and extend overall survival.



Sangjin Kim, CEO of Samjin Pharmaceutical, stated, "'Pulversed Injection' is based on an ingredient whose efficacy has been validated in global clinical trials, and it will offer a wide range of treatment options in clinical practice, from monotherapy to combination therapy with major CDK4/6 inhibitors. We will continue to do our best to improve patients' quality of life by supplying excellent pharmaceuticals backed by a diverse range of therapeutic options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing